Endocrine responses after d-fenfluramine and ipsapirone challenge: Further support for Cloninger's tridimensional model of personality

Neuropsychobiology

Volumn 41, Issue 1, 2000, Pages 38-47

  Hennig, Jürgen ^a   Toll, C ^b   Schonlau, P ^b   Rohrmann, S ^b   Netter, P ^b  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b NONE

Author keywords

Cortisol; d Fenfluramine; Ipsapirone; Personality; Prolactin

Indexed keywords

DEXFENFLURAMINE; HYDROCORTISONE; IPSAPIRONE; PROLACTIN; TROPON; UNCLASSIFIED DRUG;

ADULT; ASTHENIA; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOPAMINERGIC SYSTEM; DOUBLE BLIND PROCEDURE; FATIGUE; HUMAN; HUMAN EXPERIMENT; HYDROCORTISONE RELEASE; MALE; NEUROENDOCRINE SYSTEM; NORADRENERGIC SYSTEM; NORMAL HUMAN; PERSONALITY; PRIORITY JOURNAL; PROLACTIN RELEASE; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL; SEROTONINERGIC SYSTEM;

EID: 0033961482     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000026631     Document Type: Conference Paper

References (80)

1. Anderson GM, Mefford IN, Tolliver TJ, Riddle MA, Ocame DM, Leckman JF, Cohen DJ: Serotonin in human lumbar cerebrospinal fluid: A reassessment. Life Sci 1990;46:247-255.
2. Trulson ME: Dietary tryptophan does not alter the function of brain serotonin neurons. Life Sci 1985:37:1067-1072.
3. Stahl SM: Platelets as pharmacological models for the receptors and biochemistry for monoaminergic neurons; in Longenecker GL (ed): The Platelets: Physiology and Pharmacology. New York, Academic Press, 1985, pp 307-340.
4. De Clerck F, Xhonneux B, Leysen J, Janssen PAJ: Evidence for functional 5-HT2 receptor sites on human blood platelets. Biochem Pharmacol 1984:33:2807-2811.
5. Flament MF, Rapoport JL, Murphy DL, Berg CJ, Lake CR: Biochemical changes during clomipramine treatment of childhood obsessive-compulsive disorder. Arch Gen Psychiatry 1987;44:219-255.
6. Power AC, Cowen PJ: Neuroendocrine challenge tests: Assessment of 5-HT function in anxiety and depression. Mol Aspects Med 1992;13:205-220.
7. Coccaro EF, Kavoussi RJ: Neuropsychopharmacologic challenge in biological psychiatry. Clin Chem 1994;40:319-327.
8. Meltzer HY: Role of the serotonergic system in pituitary hormone secretion: The pharmacologic challenge paradigm in man; in Vanhoutte PM, Saxena PR, Paoletti R, Brunello N, Jackson AS (eds): Serotonin. From Cell Biology to Pharmacology and Therapeutics. Milano. Kluver Academic Publishers, 1990, pp 239-247.
9. Ryan ND. Birmaher B, Perel JM, Dahl RE, Meyer V, al Shabbout M, Iyengar S, Puig Antich J: Neuroendocrine response to L-5-hydroxytryptophan challenge in prepubertal major depression. Depressed vs normal children. Arch Gen Psychiatry 1992;49:843-851.
10. Meltzer HY, Wiita B, Tricou BJ, Simonovie M, Fang V, Manov G: Effect of serotonin precursors and serotonin agonists on plasma hormone levels. Adv Biochem Psychopharmacol 1982; 34:117-139.
11. Pitchot W, Ansseau M, Gonzalez Moreno A, Lembreghts M, Hansenne M, Wauthy J, Reel C, Jammaer R, Papart P, Sulon J, Legros JJ: The flesinoxan 5-HT1A receptor challenge in major depression and suicidal behavior. Pharmacopsychiatry 1995;28:91-92.
12. Lopez Ibor JJ Jr, Saiz Ruiz J, Iglesias LM: The renfluramine challenge test in the affective spectrum: A possible marker of endogeneity and severity. Pharmacopsychiatry 1988;21:9-14.
13. Cowen PJ: Serotonin receptor subtypes in depression: Evidence from studies in neuroendocrine regulation. Clin Neuropharmacol 1993; 16(suppl 3):S6-S18.
14. Stahl SM: Neuroendocrine markers of serotoin responsivity in depression. Prog Neuropsychopharmacol Biol Psychiatry 1992;16:655-659.
15. Rubin RT, Poland RE, Lesser IM. Martin DJ: Neuroendocrine aspects of primary endogenous depression. V. Serum prolactin measures in patients and matched control subjects. Biol Psychiatry 1989;25:4-21.
16. Van de Kar LD: Neuroendocrine aspects of the serotonergic hypothesis of depression. Neurosci Biohehav Rev 1989;13:237-246.
17. Cowen PJ, Charig EM: Neuroendocrine responses to intravenous tryptophan in major depression. Arch Gen Psychiatry 1987;44:958-966.
18. Atkinson JH Jr, Kremer EF, Risch SC, Dana R, Janowsky DS: Neuroendocrine responses in psychiatric and pain patients with major depression. Biol Psychiatry 1986;21:612-620.
19. Van Praag HM: Neurocndocrine disorders in depressions and their significance for the monoamine hypothesis of depression. Acta Psychiatr Scand 1978;57:389-404.
20. Deakin JF, Pennell I, Upadhyaya AJ, Lofthouse R: A neuroendocrine study of 5HT function in depression: Evidence for biological mechanisms of endogenous and psychosocial causation. Psychopharmacology (Berl) 1990; 101:85-92.
21. Coccaro EF: Central scrotonin and impulsive aggression. Br J Psychiatry Suppl 1989;52-62.
22. Coccaro EF: Impulsive aggression and central serotonergic system function in humans: An example of a dimensional brain-behavior relationship. Int Clin Psychopharmacol 1992;7:3-12.
23. Stein DJ, Towey J, Hollander E: The neuropsychiatry of impulsive aggression; in Hollander E, Stein DJ (eds): Impulsivity and Aggression. Chichester, Wiley, 1995, pp 91-105.
24. Fineberg NA, Cowen PJ, Kirk JW, Montgomery SA: Neuroendocrine responses to intravenous L-tryptophan in obsessive compulsive disorder. J Affective Disord 1994;32:97-104.
25. Goodman WK, McDougle CJ, Price LH, Barr LC, Hills OF, Caplik JF, Charney DS, Heninger GR: m-Chlorophenylpiperazine in patients with obsessive-compulsive disorder: Absence of symptom exacerbation. Biol Psychiatry 1995;38:138-149.
26. af Klinteberg B, Schalling D, Edman G, Oreland L, Asberg M: Personality correlates of platelet monoamine oxidase (MAO) activity in female and male subjects. Neuropsychobiology 1987;18:89-96.
27. Schalling D, Edman G, Asberg M, Oreland L: Platelet MAO activity associated with impulsivity and aggressivity. Person Individ Diff 1988;9:597-605.
28. Coursey RD, Buchsbaum MS, Murphy DL: Psychological characteristics of subjects identified by platelet MAO activity and evoked potentials as biologically at risk for psychopathology. J Abnorm Psychol 1980;89:151-164.
29. Faustman WO, King RJ, Faull KF, Moses JA Jr, Benson KL, Zarcone VP, Csernansky JG: MMPI measures of impulsivity and depression correlate with CSF 5-HIAA and HVA in depression but not schizophrenia. J Affective Disord 1991;22:235-239.
30. Linnoila VM, Virkkunen M: Aggression, suicidality, and serotonin. J Clin Psychiatry 1992; 53(suppl):46-51.
31. Fishhein DH, Lozovsky D, Jaffe JH: Impulsivity, aggression, and neuroendocrine responses to serotonergic stimulation in substance abusers. Biol Psychiatry 1989;25:1049-1066.
32. Thakore JH, O'Keane V, Dinan TG: d-Fenfluramine-induced prolactin responses in mania: Evidence for serotonergic subsensitivity. Am J Psychiatry 1996;153:1460-1463.
33. Yatham LN: Prolactin and cortisol responses to fenfluramine challenge in mania. Biol Psychiatry 1996;39:285-288.
34. Cleare AJ, Murray RM, O'Keane V: Reduced prolactin and cortisol responses to d-fenfluramine in depressed compared to healthy matched control subjects. Neuropsychopharmacology 1996;14:349-354.
35. Maes M, D'Hondt P, Suy E, Minner B, Vandervorst C, Raus J: HPA-axis hormones and prolactin responses to dextro-fenfluramine in depressed patients and healthy controls. Prog Neuropsychopharmacol Biol Psychiatry 1991; 15:781-790.
36. O'Keane V, Dinan TG: Prolactin and cortisol responses to d-fenfluramine in major depression: Evidence for diminished responsivity of central serotonergic function. Am J Psychiatry 1991;148:1009-1015.
37. Newman ME, Shapria B, Lerer B: Evaluation of central serotonergic function in affective and related disorder by the fenfluramine challenge test: A critical review. Int J Neuropharmacol 1998;1:49-69.
38. Pitchot W, Ansseau M, Gonzalez Moreno A, Lembreghts M, Hansenne M, Wauthy J, Reel C, Jammaer R, Papart P, Sulon J, et al : The flesinoxan 5-HT1A receptor challenge in major depression and suicidal behavior. Pharmacopsychiatry 1995;28(suppl 2):91-92.
39. Meltzer HY, Maes M: Effects of buspirone on plasma prolactin and cortisol levels in major depressed and normal subjects. Biol Psychiatry 1994;35:316-323.
40. Cowen PJ, Anderson IM, Grahame Smith DG: Neuroendocrine effects of azapirones. J Clin Psychopharmacol 1990;10:21S-25S.
41. Meltzer HY, Maes M: Effects of ipsapironc on plasma cortisol and body temperature in major depression. Biol Psychiatry 1995;38:450-457.
42. Lesch KP, Mayer S, Disselkamp Tietze J, Hoh A, Wiesmann M, Osterheider M, Schulte HM: 5-HT1A receptor responsivity in unipolar depression. Evaluation of ipsapirone-induced ACTH and cortisol secretion in patients and controls. Biol Psychiatry 1990;28:620-628.
43. Shiah IS, Yatham LN, Lam RW, Tam EM, Zis AP: Cortisol, hypothermic, and behavioral responses to ipsapirone in patients with bipolar depression and normal controls. Neuropsychobiology 1998;38:6-12.
44. Lesch KP, Hoh A, Disselkamp Tietze J, Wiesmann M, Osterheider M, Schulte HM:5-Hydroxytryptamine 1A receptor responsivity in obsessive-compulsive disorder. Comparison of patients and controls. Arch Gen Psychiatry 1991;48:540-547.
45. Coccaro EF, Kavoussi RJ, Hauger RL: Physiological responses to d-fenfluramine and ipsapirone challenge correlate with indices of aggression in males with personality disorder. Int Clin Psychopharmacol 1995;10:177-179.
46. Cleare AJ, Bond AJ: Does central serotonergic function correlate inversely with aggression? A study using D-fenfluramine in healthy subjects. Psychiatry Res 1997;69:89-95.
47. Netter P, Hennig J, Roed IS: Serotonin and dopaminc as mediators of sensation seeking behavior. Neuropsychobiology 1996;34:155-165.
48. Netter P, Hennig J, Rohrmann S, Wyhlidal K, Hain-Herrmann M: Modification of experimentally induced aggression by temperament dimensions. Person Individ Diff 1998;25:873-887.
49. Cloninger CR: A unified biosocial theory of personality and its role in the development of anxiety states: A reply to commentaries. Psychiatr Dev 1988;2:83-120.
50. Nelson EC, Cloninger CR, Przybeck TR, Csernansky JG: Platelet serotonergic markers and Tridimensional Personality Questionnaire measures in a clinical sample. Biol Psychiatry 1996;40:271-278.
51. Pfohl B, Black D, Noyes R Jr, Kelley M. Blum N: A test of the tridimensional personality theory: Association with diagnosis and platelet imipramine binding in obsessive-compulsive disorder. Biol Psychiatry 1990;28:41-46.
52. Davies D, Dunlop SR, Shea P, Brittain H, Hendrie HC: Biological stress responses in high and low trait anxious students. Biol Psychiatry 1985;20:843-851.
53. Netter P: Serotonin reuptake inhibitors in healthy human subjects. Adv Biol Psychiatry 1988;17:31-46.
54. McTravish D, Heel RC: Dexfenfluramine. A review of its pharmacological properties and therapeutic potential in obesity. Arch Gen Psychiatry 1992;44:573-588.
55. Hennig J, Becker H, Netter P: 5-HT agonistinduced changes in peripheral immune cells in healthy volunteers: The impact of personality. Behav Brain Res 1996;73:359-363.
56. Lesch KP, Rupprccht R, Poten B, Muller U, Sohnle K, Fritze J, Schulte HM: Endocrine responses to 5-hydroxytryptamine-1 A receptor activation by ipsapirone in humans. Biol Psychiatry 1989;26:203-205.
57. CloningerCR: A systematic method for clinical description and classification of personality variants. A proposal. Arch Gen Psychol 1987; 44:573-588.
58. Weyers P, Krebs H, Janke W: Reliability and construct validity of the German version of Cloninger's tridimensional personality questionnaire. Person Individ Diff 1995;19:853-861.
59. Muldoon MF, Manuck SB, Jansma CL, Moore AL, Perel J, Mann JJ: D,L-fenfluraminc challenge test: Experience in nonpatient sample. Biol Psychiatry 1996;39:761-768.
60. Armario A, Marti O, Molina T, de Pablo J, Valdes M: Acute stress markers in humans: Response of plasma glucose, cortisol and prolactin to two examinations differing in the anxiety they provoke. Psychoneuroendocrinology 1996;21: 17-24.
61. Brooks JE, Herbert M, Walder CP, Selby C, Jeffcoate WJ: Prolactin and stress: Some endocrine correlates of pro-operative anxiety. Clin Endocrinol (Oxf) 1986;24:653-656.
62. Meyerhoff JL, Oleshansky MA, Mougey EH: Psychologic stress increases plasma levels of prolactin, cortisol. and POMC-derived peptides in man. Psychosom Med 1988;50:295-303.
63. Goodwill GM, Murray CL, Bancroft J: Oral D-fenfluramine and neuroendocrine challenge: problems with the 30 mg dose in men. J Affective Disord 1994;30:117-122.
64. Brooks A, Meyer T, George G, Hillmer-Vogel U, Meyer D, Bandelow B, Hajak G, Bartmann U, Gleiter CH, Ruether E: Decreased neuroendocrine responses to meta-chlorphenylpiperazine (mCPP) but normal responses to ipsapirone in marathon runners. Neuropsychopharmacology 1999;20:150-161.
65. Goodall EM, Cowen PJ, Franklin M, Silverstone T: Ritanserin attenuates anorectic, endocrine and thermic responses to d-fenfluramine in human volunteers. Psychopharmacology 1993;112:461-466.
66. Coccaro EF, Kavoussi RJ, Oakes M, Cooper TB, Hauger R: 5-HT 2a/2c receptor blockade by amesergide fully attenuates prolactin response to d-fenfluramine challenge in physically healthy human subjects. Psychopharmacology 1996;126:24-30.
67. Monteleone P, Bortolotti F, Orazzo C, Serino I, Maj M: Differences between morning and afternoon hormonal responses to D-fenfluramine in healthy humans. Psychoneuroendocrinology 1997;22:79-87.
68. Monteleone P, La Rocca A, Fuschino A, Bortolotti F, Maj M: Seasonal variation in plasma prolactin response to d-fenfluramine in healthy subjects. Psychoneuroendocrinology 1999;24: 201-208.
69. Beneke M, Wingender W, Horstmann R, Konrad Dalhoff I, Weber H, Kuhlmann J, Schmidt BH: Neuroendocrine effects of ipsapirone on the hypothalamic-pituitary adrenal axis: CRF, ACTH and cortisol in healthy volunteers. Eur J Clin Pharmacol 1992;42:163-169.
70. Kahn RS, Trestman R, Lawlor BA, Gabriel S, Davidson M, Siever L: Effects of ipsapirone in healthy subjects: A dose-response study. Psychopharmacology (Berl) 1994;114:155-160.
71. Gelfin Y, Lerer B. Leseh KP, Gorfine M, Allolio B: Complex effects of age and gender on hypothermic, adrenocorticotrophic hormone and cortisol responses to ipsapirone challenge in normal subjects. Psychopharmacology (Berl) 1995;120:356-364.
72. Coccaro EF, Silverman JM, Klar HM, Horvath TB, Siever LJ: Familial correlates of reduced central serotonergic system function in patients with personality disorders. Arch Gen Psychiatry 1994;51:318-324.
73. Coccaro EF, Berman ME, Kavoussi RJ, Hauger RL: Relationship of prolactin response to d-fenfluramine to behavioral and questionnaire assessments of aggression in personalitydisordered men (see comments). Biol Psychiatry 1996;40:157-164.
74. Coccaro EF, Kavoussi RJ, Trestman RL, Gabriel SM, Cooper TB, Siever LJ: Serotonin function in human subjects: Intercorrelations among central 5-HT indices and aggressiveness. Psychiatry Res 1997;73:1-14.
75. Gerra G, Caccavari R, Zaimovic A, Palladino M. Chittolini B. Giucastro G. Maestri D, Monica C, Fertonani Affini G, Delsignore R, Bramhilla F: Serotonergic function in mothers of opioid addicts: Correlation with comorbid depression. Acta Psychiatr Scand 1997:96:36-42.
76. Malone KM, Corhitt EM, Li S, Mann JJ: Prolactin response to fenfluramine and suicide attempt lethality in major depression. Br J Psychiatry 1996;168:324-329.
77. Mann JJ, McBride PA, Malone KM, DeMeo M, Keilp J: Blunted serotonergic responsivity in depressed inpatients. Neuropsychopharmacology 1995;13:53-64.
78. Coccaro EF, Kavoussi RJ, Cooper TB, Hauger RL: Central serotonin activity and aggression: Inverse relationship with prolactin response to d-fenfluramine. but not CSF 5-HIAA concentration, in human subjects. Am J Psychiatry 1997;154:1430-1435.
79. Yatham LN, Steiner M: Neuroendocrine probes of serotonergic function: A critical review. Life Sci 1993;53:447-463.
80. Mitchell PB, Smythe GA: Endocrine and amine responses to D.L-fenfluramine in normal subjects. Psychiatry Res 1991:39:141-153.